ArticleArthritis research & therapy2016
Incidence and prevalence of gout in Western Sweden.
Article in Arthritis research & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 111 citations in OpenAlex.
- Evaluation of the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Firsekibart in Gout: A Phase Ib/II Clinical Trial.International journal of rheumatic diseases · 2026Trial
- Baseline Dual-Energy Computed Tomography Urate Volume Predicts Fulfillment of Gout Remission After Two Years of Urate-Lowering Therapy.Arthritis care & research · 2024Trial
- Effectiveness of an electronic patient-centred self-management tool for gout sufferers: a cluster randomised controlled trial protocol.BMJ open · 2017Trial
- Peripheral CD4Frontiers in immunology · 2026Article
- Multiple comorbidities and economic burden of hospitalized gout patients in Guangdong Province.Clinical rheumatology · 2025Article
- The global burden and epidemiological trends of gout, particularly cases attributable to high Body Mass Index (BMI) in adolescents and young adults (aged 15-39 years): a secondary analysis from global burden of disease study 2021.Clinical rheumatology · 2025Article
- 'All I Do Is Sit in a Chair Until the Pain Fades'-Experiences of Living With Gout.Health expectations : an international journal of public participation in health care and health policy · 2025Article
- Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study.Rheumatology (Oxford, England) · 2025Observational
- Gout, Hyperuricemia and Psoriatic Arthritis: An Evolving Conundrum.Current rheumatology reports · 2025Review
- Assessing cross-national inequalities and predictive trends in gout burden: a global perspective (1990-2021).Frontiers in medicine · 2025Article
- Gout: global epidemiology, risk factors, comorbidities and complications: a narrative review.BMC musculoskeletal disorders · 2024Review
- Single photon emission computed tomography/computed tomography imaging of gouty arthritis: A new voice.Journal of translational internal medicine · 2024Article
- Global burden and epidemic trends of gout attributable to high body mass index from 1990 to 2019.Archives of medical science : AMS · 2024Article
- Causal impact of human blood metabolites and metabolic pathways on serum uric acid and gout: a mendelian randomization study.Frontiers in endocrinology · 2024Article
- Course and predictors of work productivity in gout - results from the NOR-Gout longitudinal 2-year treat-to-target study.Rheumatology (Oxford, England) · 2023Article
- Causal Relationship between Gut Microbiota and Gout: A Two-Sample Mendelian Randomization Study.Nutrients · 2023Article
- Global, Regional, and National Prevalence of Gout From 1990 to 2019: Age-Period-Cohort Analysis With Future Burden Prediction.JMIR public health and surveillance · 2023Article
- Gender differences in illness perceptions and disease management in patients with gout, results from a questionnaire study in Western Sweden.BMC musculoskeletal disorders · 2023Article
- Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study.Clinical rheumatology · 2022Article
- Treatment for hyperuricemia and gout in Japan: Aspect of prescription and duration.Journal of clinical hypertension (Greenwich, Conn.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of the present study was to describe prevalence and trends in the incidence of gout and patterns of urate-lowering treatment (ULT) in the Western Swedish Health Care Region (WSHCR) from 2002 to 2012.
methodsWe used regional and national healthcare registers to estimate the prevalence and incidence of gout in 2012, and trends in incidence for each calendar year from 2005 to 2012. We also investigated the pattern of ULT for gout using the Swedish Prescribed Drug Register.
resultsIn 2012, in the population aged 20 years and above, the prevalence of gout was 1.8 % (95 % confidence interval (CI) 1.77 to 1.82) and the incidence was 190 cases (95 % CI 180 to 200) per 100,000 person-years. Applying more strict definitions for a gout case rendered a prevalence of 1.36 % (95 % CI 1.34 to 1.38) and 0.5 (95 % CI 0.49 to 0.51) per 100,000 person-years, respectively. The incidence of gout increased steadily and significantly from 2005 to 2012, with an almost 50 % increase in the total population. There was no significant difference in the prevalence of gout in rural compared to urban areas. ULT was dispensed to only 42 % of patients with gout in 2012 who had ever been diagnosed with gout during the preceding 10-year period.
conclusionsGout is the most common arthritic disease in WSHCR, Sweden, and has increased substantially over the last decade, with only a minority of prevalent cases in 2012 receiving ULT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.